Risk factors for thiopurine‐induced myelosuppression and infections in inflammatory bowel disease patients with a normal TPMT genotype

BACKGROUND: Leucopenia is a common side effect in patients treated with thiopurines. Variants in the thiopurine S‐methyltransferase (TPMT) gene are the best‐known risk factor, but only explain up to 25% of leucopenia cases. AIM: To identify the clinical risk factors for thiopurine‐induced leucopenia...

詳細記述

保存先:
書誌詳細
出版年:Aliment Pharmacol Ther
主要な著者: Broekman, M. M. T. J., Coenen, M. J. H., Wanten, G. J., van Marrewijk, C. J., Klungel, O. H., Verbeek, A. L. M., Hooymans, P. M., Guchelaar, H.‐J., Scheffer, H., Derijks, L. J. J., Wong, D. R., de Jong, D. J.
フォーマット: Artigo
言語:Inglês
出版事項: John Wiley and Sons Inc. 2017
主題:
Thiopurine Myelosuppression and Infections in IBD
オンライン･アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC5698717/
https://ncbi.nlm.nih.gov/pubmed/28914446
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/apt.14323
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!

類似資料